Abstract 11923: Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study
Introduction: Perceived discrimination is known to play a role in the development of cardiovascular (CV) risk factors such as hypertension, but the association with CV outcomes is less clear. A recent report from a multi-ethnic cohort study found a modestly increased risk of CV disease in participants reporting discrimination. We explored this association in an African American (AA) cohort.
Hypothesis: Greater perceived discrimination is associated with a higher risk of CV disease
Methods: We examined CV outcomes among 5085 AAs in the Jackson Heart Study enrolled in 2000-2004 and followed through December 31, 2012. We stratified participants by quartiles of perceived everyday discrimination and estimated the associations with CV outcomes (all-cause mortality, incident coronary heart disease [CHD], incident stroke, and heart failure [HF] hospitalization) using Cox models.
Results: Greater perceived discrimination was more common in participants who were younger, male, had higher education and income, a lower perceived standing in the community, worse perceived healthcare access, and fewer comorbidities. Over a median follow-up of 9.8 years (8.0 years for HF), 573 deaths, 193 incident CHD, 156 incident strokes, and 348 HF hospitalizations occurred. Prior to adjustment, greater perceived discrimination was associated with a lower risk of death, incident CHD, stroke, and HF hospitalization (Table). After adjustment for potential confounders, we found no association of perceived discrimination with incident CHD, stroke or HF hospitalization; however, a decrease in all-cause mortality risk with higher perceived discrimination persisted.
Conclusions: We found no independent association of perceived discrimination with risk of incident CV disease or HF hospitalization and a paradoxical negative association with mortality in this AA population. The unexpected finding of a lower risk of death with greater perceived discrimination requires further study.
Author Disclosures: S.M. Dunlay: None. S.J. Lippmann: None. M.A. Greiner: None. E.C. O’Brien: None. A.M. Chamberlain: None. R.J. Mentz: Other Research Support; Modest; Amgen, Aztra Zeneca, Bristol Meyers Squibb, GlaxoSmithKline, Gilead, Medtronic, Novartis, Otsuka, ResMed. Honoraria; Modest; HeartWare, Janssen, Luitpold Pharmaceuticals, Novartis, ResMed, Thoratec/ St Jude. Consultant/Advisory Board; Modest; Luitpold Pharmaceuticals. M. Sims: None.
- © 2016 by American Heart Association, Inc.